

				)	
Form PTO-1449 Modified			Docket No. CELL-0271/PA 514	Application No. 10/620,533	
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)			Applicant Julien Alistair Brown, et al.		
U.S. Department of Commerce Patent and Trademark Office			Filing Date July 16, 2003	Group Not-Yet Assigned ) 626	
			Confirmation No. Not Yet Assigned		
ОТ	THE	R DOCUMENTS (Includ	ing Author, Title, Date,	Pertinent Pages, Etc.)	
Sfe	1			gen-Induced Late Bronchial eness in Sheep," J. Clin. Invest.,	
盤	2	Berlin, C. et al., "α4β7 Integrin Mediates Lymphocyte Binding to the Mucosal Vascular Addressin MAdCAM-1," Cell, 1993, 74, 185-195			
888	3	Binns, R.M. et al., "The Role of E-Selectin in Lymphocyte and Polymorphonuclear Cell Recruitment into Cutaneous Delayed Hypersensitivity Reactions in Sensitized Pigs," J. Immunol., 1996, 157, 4094-409			
in 888	4	to its lymphocyte receptor $\alpha_4\beta_7$ ," J. Immunol., 1996, 156, 719-726			
328	5	Brooks, Peter C., et al., "Antiintegrin avß3 blocks human breast cancer growth and angiogenesis in human skin," J. Clin. Invest., 1995, 96, 1815-1822			
288	6	Cardarelli, P.M. et al., "Cyclic RGD Peptide Inhibits α4β7 Interaction with Connecting Segment 1 and Vascular Cell Adhesion Molecule," J. Biol. Chem., 1994, 269(28), 18668-18673			
#28	7	Erle, D.J., et al., "Expression and function of the MadCAM-1 receptor, integrin α4β7, on human leukocytes," J. Immunol., 1994, 153, 517-528			
£2 £2	8	Ferguson, T.A. et al., "Two integrin-binding peptides abrogate T cell-mediated immune responses in vivo," Proc. Natl. Acad. Sci. USA, 1991, 88, 8072-8076			
&S	9	Hammes, H., et al., "Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization," <i>Nature Medicine</i> , 1996, 2, 529-533			
**	10	Hesterberg, P.E., et al., "Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin α4β7," Gastroenterol, 1996, 111, 1373-1380			
EXAMINER	X	aun f. Stockt	DATE CONS	SIDERED 9/23/04	



Form PTO-1449 Modified			Docket No. CELL-0271/PA 514	Application No. 10/620,533	
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)			Applicant Julien Alistair Brown, et al.		
U.S. Department of Commerce Patent and Trademark Office			Filing Date July 16, 2003	Group Nor Yer Assigned 1626	
			Confirmation No. Not Yet Assigned		
0	THE	R DOCUMENTS (Includ	ling Author, Title, Date,	Pertinent Pages, Etc.)	
<del>82</del> 3	11	Hodivala-Dilke, K.M., "β3-integrin-deficient mice are a model for glanzmann thrombasthenia showing placental defects and reduced survival," J. Clin. Invest., 1999, 103(2), 229-238			
<b>B</b> S	12	Holzmann, B., et al., "Peyer's patch-specific lymphocyte homing receptors consist of a VLA-4-like α chain associated with either of two integrin ß chains, one of which is novel," <i>EMBO J.</i> , 1989, 8(6), 1735-1741			
***	13	Humphries, M.J. et al., "Mechanisms of VCAM-1 and fibronectin binding to integrin $\alpha_4\beta_1$ : implications for integrin function and rational drug design," Ciba Foundation Symposium, 1995, 189, 177-194			
\$2	14	Issekutz, T.B., "Inhibition of Lymphocyte Endothelial Adhesion and In Vivo Lymphocyte Migration to Cutaneous Inflammation by TA-3, a New Monoclonal Antibody to Rat LFA-1," J. Immunol., 1992, 149(10), 3394-3402			
<u>AL</u>	15	Li, Z. et al., "Effect of an anti-Mo1 MAb on ozone-induced airway inflammation and airway hyperresponsiveness in dogs," Am. J. Physiol., 1992, 263(6 Pt 1), L723-726			
Se	16	Marlin, S.D. et al., "LFA-1 Immunodeficiency Disease," J. Exp. Med., 1986, 164, 855-867			
<b>8</b> 8	17	the development of a human melanoma in nude mice," J. Cell Science, 1995, 108, 2825-2838			
<b>8</b> 6		Newham, P., et al., "Integrin adhesion receptors: structure, function and implications for biomedicine," <i>Molecular Medicine Today</i> , 1996, 304-313			
AL.	19	Osborne, L., "Leukoctye Adhesion to Endothelium in Inflammation," Cell, 1990, 62, 3-6			
Æ	20	Podolsky, D.K. et al., "Attenuation of Colitis in the Cotton-top Tamarin by Anti-α4 integrin Monoclonal Antibody," J. Clin. Invest., 1993, 92, 372-380			
EXAMINER <sub>(</sub>	Za	und-Stock	DATE CON	<del></del>	



Form PTO-1449 Modified			Docket No. CELL-0271/PA 514	Application No. 10/620,533	
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)			Applicant Julien Alistair Brown, et al.		
U.S. Department of Commerce Patent and Trademark Office			Filing Date July 16, 2003	Group Not Yot Assigned 626	
			Confirmation No. Not Yet Assigned		
-, -	OTHE	R DOCUMENTS (Incl	uding Author, Title, Date,	Pertinent Pages, Etc.)	
<del>\$</del> }	21	Shroff, H.N., et al., "Small peptide inhibitors of α <sub>4</sub> β <sub>7</sub> mediated MadCAM-1 adhesion to lymphocytes," <i>Biorg. Med. Chem. Letts.</i> , <b>1996</b> , 6(21), 2495-2500			
<b>8</b> 8	22	Sonnenberg, A., "Integrins and their ligands," Curr. Topics Microbiol. Immunol., 1993, 184, 7-35			
£6	23	Springer, T.A., "Adhesion receptors of the immune system," Nature, 1990, 346, 425-434			
<b>B</b> B	24	Springer, T.A., "Traffic Signals for Lymphocyte Recirculation and Leukocyte Emigration: The Multistep Paradigm," Cell, 1994, 76, 301-314			
<b>X</b>	25	Srivatsa, S.S., et al., "Selective $\alpha v \beta 3$ integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin $\alpha v \beta 3$ and osteopontin expression during neointima formation," Cariovascular Research, 1997, 36, 408-428			
<del>88</del> 8	26	Vanderslice, P. et al., "A Cyclic Hexapeptide is a Potent Antagonist of α4 Integrins,"  J. Immunol., 1997, 158, 1710-1718			
搬	27				
R	28	Yang, X., "A predominant role of integrin α4 in the spontaneous development of autoimmune diabetes in nonobese diabetic mice," <i>Proc. Natl. Acad. Sci. USA</i> , 1994, 91, 12604-12608			
<b>&amp;</b>	29	Yednock, T.A., "Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin," <i>Nature</i> , <b>1992</b> , 356, 63-66			
			· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	
XAMINEI	$R \not \to \infty$	un L. Stor	DATE CON	ISIDERED 9/23/04	



Form PTO-1449 Modified				Docket No. CELL-0271/PA 514	Application No. 10/620,533		
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office				Applicant Julien Alistair Brown, et al.			
				Filing Date July 16, 2003  Group Not Yet Assigned			
				Confirmation No. Not Yet Assigned			
		U.	S. PATENT	T DOCUMENTS			
Examiner Initial		Document No.	Date	Name	Class	Subclass	
	-						
			<del> </del>				
	-						
لــــــل		FORE	IGN PATI	ENT DOCUMENTS			
Examiner					ranslation		
Initial		Document No.	Date	Country	YES	NO	
SEC .	30	WO 02/068393 A1	09/06/02	PCT			
	-		1				
	~~~						
EXAMINER	₹	aun L Sta	Kton	DATE CONSIDERI	$\mathbf{SD} = 9/23$	3/04	